Brief: Aligos Therapeutics Presents Data From Liver Disease Programs
21/06/2023 22:33
June 21 (Reuters) - Aligos Therapeutics Inc ALGS.O :
* ALIGOS THERAPEUTICS PRESENTS DATA FROM ITS LIVER DISEASE
PROGRAMS AT THE EUROPEAN ASSOCIATION FOR THE STUDY OF THE LIVER
(EASL) CONGRESS 2023
* ALIGOS THERAPEUTICS INC- ALG-000184 CONTINUES TO
DEMONSTRATE A
FAVORABLE SAFETY AND PHARMACOKINETIC (PK) PROFILE OVER EXTENDED
DOSING DURATIONS
Source text for Eikon: ID:nGNX8NQ4n3
Further company coverage: ALGS.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Aligos Therapeutics
See all newsUS FDA approves GSK's hepatitis B drug, offering patients chance to stop long-term treatment (updated)
U.S. RESEARCH ROUNDUP-Ciena Corp, Docusign, Snowflake
Brief: Aligos Therapeutics Announces First Participant Dosed In The Phase 1 Study Of Its Potentially Best-In-Class Antisense Oligonucleotide Alg-170675 By Its Partner Amoytop In China
Aligos Therapeutics, Inc. reports results for the quarter ended June 30 - Earnings Summary
Aligos Therapeutics Q2 net loss narrows on licensing revenue